What did @keli.holston actually say?
Honestly, not much, medically speaking. The entire spoken transcript is: "Look, it's just me versus me. And best believe I'm coming out on top every time." That's a motivational statement, not a health claim. The medical context comes entirely from the hashtags: semaglutidejourney, semaglutidetransformation, semaglutideforweightloss. Combined with a five-month before-and-after visual comparison, the implicit claim is that semaglutide produced a meaningful body composition change over that period. No dosage mentioned, no side effects disclosed, no clinical framing. Just results and a mindset quote.
To be clear, the absence of explicit medical claims is actually the safest thing about this video. But the before-and-after format makes an argument on its own, and that argument deserves scrutiny.
Does the science back this up?
A visible body composition change over five months on semaglutide? Yes, the clinical data supports that this is plausible and fairly common. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that participants on 2.4 mg weekly semaglutide lost an average of 14.9% of body weight over 68 weeks. At five months, you'd expect to be somewhere in the middle of that trajectory.
Earlier phases of GLP-1 treatment tend to show the steepest weight loss curves. A secondary analysis from the STEP program showed that participants lost roughly 5-9% of body weight within the first 12-20 weeks, depending on dose titration. So a visible difference between January and April is consistent with what researchers have actually measured, not just anecdote. The "me versus me" framing also reflects something real: weight loss outcomes on semaglutide vary significantly by individual, with some losing twice the average and others losing very little (Rubino et al., 2022, JAMA).
What did they get wrong (or right)?
There is nothing factually wrong here because there are almost no factual claims. What @keli.holston got right, probably without thinking about it, is the framing. "Me versus me" is actually clinically appropriate. GLP-1 response is highly individual. Comparing your results to someone else's TikTok transformation is one of the more counterproductive things a patient can do.
What is missing is context that would make this video genuinely useful rather than just visually compelling. Five months is still early. The STEP 1 data shows that weight regain after stopping semaglutide is substantial: participants regained about two-thirds of lost weight within a year of discontinuation (Wilding et al., 2022, Diabetes, Obesity and Metabolism). That's not a reason not to use it, but it's information that belongs somewhere in the conversation around these transformation posts. The video implies a destination. The research suggests it's more of an ongoing process.
What should you actually know?
If you're watching this video and wondering whether your own results will look like this, here is what the evidence actually says:
- Average weight loss on semaglutide at 2.4 mg weekly is around 15% of starting body weight over about 16 months, but individual variation is significant (Wilding et al., 2021, NEJM).
- Five months is typically still within the active loss phase for most patients, not a plateau, so early results can look dramatic and then slow considerably.
- Semaglutide does not produce identical results for everyone. Factors including baseline metabolic health, adherence, diet, and activity all influence outcomes (Rubino et al., 2022, JAMA).
- Before-and-after videos on social media represent a heavily self-selected group. People who see dramatic results post them. People who don't, largely don't. This is survivorship bias, and it is rampant in GLP-1 content.
- Body composition changes matter as much as scale weight. Some of the weight lost on GLP-1 medications is lean muscle mass, particularly without resistance training (Bikou et al., 2023, Nutrients). That's a clinical consideration worth discussing with a provider.
None of this is a reason to dismiss what @keli.holston shared. The transformation is real and the mindset framing is reasonable. But a 36,000-view video carries responsibility that a private journal entry doesn't, and that context gap is worth naming.